Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Compaq -- Ignore unavailable to you. Want to Upgrade?

To: PCSS who wrote (93216)	9/28/2001 10:23:01 AM
From: Elwood P. Dowd	Respond to of 97611

Prominent Merck and Compaq Executives to Keynote Region's Largest Biotechnology Investor Conference, MASS Opportunities -- Merck's Dr. Bennett M. Shapiro to focus on innovative pharmaceutical- biotechnology collaborations, Compaq's Bill Blake to highlight computing technology's vital role in genomics -- CAMBRIDGE, Mass., Sept. 27 /PRNewswire/ -- The 2001 edition of MASS Opportunities, the annual investor conference sponsored by the Massachusetts Biotechnology Council, will offer for the first time keynote speakers at both conference luncheons. MASS Opportunities will take place October 30-31, 2001, at the Hilton Boston Logan Airport, Boston, Massachusetts. On October 30 Dr. Bennett M. Shapiro will address the hundreds of portfolio managers, analysts, venture capitalists, other investment professionals, and representatives of biotech companies in attendance. Dr. Shapiro is Executive Vice President, Worldwide, Licensing and External Research, Merck Research Laboratories, Merck & Company, Inc. (NYSE: MRK - news). On October 31, the luncheon keynote will be Bill Blake, Vice President, Worldwide High Performance Technical Computing, Compaq Corporation (NYSE: CPQ - news). Janice Bourque, President of the Massachusetts Biotechnology Council, said the prominent speakers reflect an enhanced stature of MASS Opportunities as the region's premier venue for bringing together the biotech and investor communities. ``We have continued to upgrade the conference, whose essential goal remains to facilitate interaction between the companies and investors,'' said Ms. Bourque. ``By adding new programs and speakers of interest we hope to add more value to a conference that has already enjoyed great success its first two years.'' Dr. Shapiro, who has held leading research positions at Merck since 1990, is expected to talk about the dynamic of the growing trend toward collaborations and partnerships between the pharmaceutical and biotechnology industries. At Merck, Dr. Shapiro is optimizing the use of extended research networks of several types. Observers have a keen interest in hearing Mr. Blake's comments, which are expected to focus on bioinformatics and other converging technologies that have become more prominent in the biotech sector. Mr. Blake and Compaq were key players in dramatically compressing the schedule of the human genome project through aggressive and large-scale application of high performance computing technology to the genome sequencing effort. Both luncheons are co-sponsored by the law firm of Ropes and Gray and by The American Stock Exchange (AMEX). To register for this conference or for more information visit the Massachusetts Opportunities Conference webpage at: (http://www.massopps.com) or contact the Massachusetts Biotechnology Council at: (617) 577-8198. Founded in 1985, the MBC is a not-for-profit trade association that provides service and support to the Massachusetts biotechnology industry. The MBC is committed to helping its members advance the development of new science, technology and medicines that benefit people and patients worldwide. Representing over three hundred companies, academic institutions and other organizations involved in biotechnology and health care, the MBC conducts outreach, works with policy and public health leaders, sponsors educational forums and provides member services to achieve its goals. Contacts: Stephen Mulloney Director of Communications Massachusetts Biotechnology Council (617) 577-8198 www.massbio.org Chris Erdman (Investor Contact) Michael Mitchell (Media Contact) Feinstein Kean Healthcare (617) 577-8110 www.fkhealth.com SOURCE: Massachusetts Biotechnology Council